Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Monopar Therapeutics Inc. (MNPR) vs Neurogene Inc. (NGNE)

Monopar Therapeutics Inc. and Neurogene Inc. are both Biotechnology companies. Monopar Therapeutics Inc. and Neurogene Inc. are of similar size ($625.4M and $602.8M). Across the 8 metrics below, Monopar Therapeutics Inc. leads on 6 and Neurogene Inc. on 2.

Valuation

Metric MNPR NGNE Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 5.56 2.94 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m n/m 10.73
Earnings yield (2.55%) (17.79%) (28.84%)
Free cash flow yield (1.67%) (13.76%) (23.03%)

Profitability

Metric MNPR NGNE Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (19.50%) (45.32%) (57.72%)
Return on assets (18.90%) (41.02%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MNPR NGNE Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 54.99% 0.93% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MNPR NGNE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 33.56 10.64 4.73
Net debt to EBITDA 8.06 2.57 0.96

Dividend

Metric MNPR NGNE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric MNPR NGNE Biotechnology median
Market cap 602.75m 625.36m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack